Drug Coverage: Plans And PBMs Cheer, Big Pharma Jeers Guidelines

Article Overview

This article covers the final United States Pharmacopeia guidance for Medicare Part D drug categories, classes, and related key drug types, along with how CMS and industry stakeholders responded. It is relevant to Medicare formulary stakeholders, health plans, pharmacy benefit managers, pharmaceutical manufacturers, and coding or compliance professionals tracking Part D coverage policy. The discussion focuses on the structure of the classification framework, the role of the safe harbor, and the policy debate around how the guidance may be interpreted and applied.